4.7 Article

Highlights from a year in a pandemic

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Multidisciplinary Sciences

Global absence and targeting of protective immune states in severe COVID-19

Alexis J. Combes et al.

Summary: Patients with mild COVID-19 exhibit a coordinated pattern of expression of interferon-stimulated genes (ISGs) across every cell population, whereas these ISG-expressing cells are systemically absent in patients with severe disease. Individuals with severe COVID-19 produce very high titres of anti-SARS-CoV-2 antibodies and have a lower viral load compared to individuals with mild disease.

NATURE (2021)

Article Medicine, General & Internal

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

D. M. Weinreich et al.

Summary: Recent data indicate that complications and death from Covid-19 may be related to high viral loads. In this trial involving nonhospitalized patients, a cocktail of two neutralizing monoclonal antibodies (REGN-COV2) reduced viral load, with a greater effect in patients with no immune response or high viral load at baseline. Safety outcomes were similar between REGN-COV2 dose groups and the placebo group.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

News Item Biotechnology & Applied Microbiology

Trends in COVID-19 therapeutic clinical trials

Kevin Bugin et al.

NATURE REVIEWS DRUG DISCOVERY (2021)

Article Multidisciplinary Sciences

Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A

Kris M. White et al.

Summary: The study revealed that plitidepsin possesses potent antiviral activity against SARS-CoV-2, more effective than the approved drug remdesivir. By inhibiting the eukaryotic translation elongation factor 1A, plitidepsin can significantly reduce viral replication of SARS-CoV-2 in the lungs of mice, making it a promising candidate for COVID-19 treatment.

SCIENCE (2021)

Article Immunology

The first 12 months of COVID-19: a timeline of immunological insights

Thiago Carvalho et al.

Summary: The timeline of major scientific discoveries during the first year of the COVID-19 pandemic highlights the collaborative efforts that led to rapid progress in understanding the immune response to SARS-CoV-2. It showcases the unprecedented convergence of research efforts on COVID-19 and identifies gaps in knowledge for future investigations.

NATURE REVIEWS IMMUNOLOGY (2021)

Article Multidisciplinary Sciences

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

David E. Gordon et al.

NATURE (2020)

Article Biochemistry & Molecular Biology

Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19

Aymeric Silvin et al.

Article Pathology

In situ detection of SARS-CoV-2 in lungs and airways of patients with COVID-19

Inga-Marie Schaefer et al.

MODERN PATHOLOGY (2020)

Article Multidisciplinary Sciences

Longitudinal analyses reveal immunological misfiring in severe COVID-19

Carolina Lucas et al.

NATURE (2020)

Article Biochemistry & Molecular Biology

An inflammatory cytokine signature predicts COVID-19 severity and survival

Diane Marie Del Valle et al.

NATURE MEDICINE (2020)

Article Multidisciplinary Sciences

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

Qian Zhang et al.

SCIENCE (2020)

Article Multidisciplinary Sciences

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Paul Bastard et al.

SCIENCE (2020)

News Item Multidisciplinary Sciences

COVID IN PAPERS: A TORRENT OF SCIENCE

Holly Else

NATURE (2020)

Article Multidisciplinary Sciences

Temporal and spatial heterogeneity of host response to SARS-CoV-2 pulmonary infection

Niyati Desai et al.

NATURE COMMUNICATIONS (2020)